Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667342 · ClinicalTrials.gov registry record · Phase 2
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00667342 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 43 participants.
The verdict
NCT00667342, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF). Chemotherapy for localized disease comprises a 3-drug regimen (cisplatin, doxorubicin, and high-dose methotrexate). Chemotherapy for metastatic or unresectable disease comprises a cisplatin-based regimen that includes high-dose methotrexate, doxorubicin, ifosfamide, and etoposide.
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Ifosfamide
- BIOLOGICAL Bevacizumab
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2008-06-03 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667342
The ClinicalTrials.gov registry entry for NCT00667342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00667342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667342 about?
NCT00667342 is a clinical study titled "A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma". This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF). Chemotherapy for localized disease comprises a 3-drug re...
What is the current status of trial NCT00667342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2008-06-03. Estimated completion is 2017-08.
What interventions are being tested in trial NCT00667342?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Ifosfamide (DRUG), Bevacizumab (BIOLOGICAL), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00667342?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.